The findings suggest that lymphocyte infiltration and the status of IFN-γ are critical factors in assessing the effectiveness of anti-PD-1 or anti-PD-L1 therapies in ovarian cancer.58 This dynamic modulation of immunological checkpoints allows malignancies to avoid immune surveillance and maintain an immunosuppressive microenvironment. This evidence concerns the gene PDCD1 and ovarian cancer.